UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~May 14~~June 3, 2025

scPharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-38293	46-5184075
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

25 Mall Road, Suite 203 Burlington, Massachusetts		01803
(Address of principal executive offices)		(Zip Code)

25 Mall Rd., Suite 203

Burlington, Massachusetts 01803

(Address of principal executive offices) (Zip Code)

(617) 517-0730

(Registrant’s telephone number, ~~including~~include area code)

N/A

(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	TradingSymbol(s)	Name of each ~~exchangeon~~exchange on which registered
Common stock, par value $0.0001 per share	SCPH	The Nasdaq Global Select Market
Common Stock, par value $0.0001 per share	SCPH	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0207. ~~Results~~Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition~~Vote of Security Holders.

On ~~May~~June 143, 2025, scPharmaceuticals Inc. ~~announced~~(the “Company”) held its ~~financial~~Annual ~~results~~Meeting ~~for~~of Stockholders. A total of 35,156,523 shares of common stock were present online or represented by proxy at the ~~quarter~~meeting, ~~ended~~representing ~~March~~approximately 69.91% percent of the Company’s outstanding common stock as of the April 317, 2025 record date. The ~~full~~following ~~text~~are ofthe voting results for the ~~press~~proposals ~~release~~considered ~~issued~~and invoted ~~connection~~upon ~~with~~at the ~~announcement~~meeting, isall ~~furnished~~of aswhich ~~Exhibit~~were ~~99.1~~described toin ~~this~~the ~~Current~~Company’s ~~Report~~definitive proxy statement filed with the Securities and Exchange Commission on ~~Form~~April 21, ~~8-K~~2025.

~~The~~Proposal ~~information~~1 ~~contained in Item 2.02 of this Current Report on Form 8~~-K ~~(including~~Election ~~Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes~~ of ~~Section~~three Class 18II ofDirectors ~~the~~to ~~Securities~~serve ~~Exchange~~until ~~Act of 1934, as amended (~~the ~~“Exchange~~2028 ~~Act”),~~Annual orMeeting ~~otherwise subject to the liabilities~~ of ~~that section~~Stockholders, ~~nor~~and ~~shall~~until ittheir berespective ~~deemed~~successors ~~incorporated~~have bybeen ~~reference~~duly inelected ~~any~~and ~~filing~~qualified ~~under~~or ~~the~~until ~~Securities~~their ~~Act~~earlier ofresignation ~~1933, as amended,~~ or ~~the Exchange Act, except as expressly provided by specific reference in such a filing~~removal.

Item 9.01 Financial Statements and Exhibits.


NOMINEE	FOR		WITHHELD		Broker Non-Votes
William T. Abraham, M.D.		23,663,867		4,580,804		6,911,852
Mette Kirstine Agger		23,083,224		5,161,447		6,911,852
Minnie Baylor-Henry		27,995,209		249,462		6,911,852

~~(d)~~Proposal ~~Exhibits~~2 - Ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed:


FOR	AGAINST	ABSTAINED	Broker Non-Votes
35,050,989	89,548	15,986	0

ExhibitNo.		Description
99.1		Press Release of scPharmaceuticals Inc. issued May 14, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

Proposal 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.


FOR	AGAINST	ABSTAINED	Broker Non-Votes
27,995,161	238,938	10,572	6,911,852

Based on the foregoing votes, William T. Abraham, M.D., Mette Kirstine Agger and Minnie Baylor-Henry were elected as Class II Directors, and Proposals 2 and 3 were approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCPHARMACEUTICALS INC.
Date: May 14, 2025	By:	/s/ John H. Tucker
Date: June 9, 2025	By:	/s/ John H. Tucker
	Name:	John H. Tucker
		John H. Tucker
	Title:	President and Chief Executive Officer
		President and Chief Executive Officer

Filing Compare · scPharmaceuticals Inc.